Calls for papers
-
MannKind Corporation announced a strategic financing agreement with Blackstone that will provide the company with a $75 million loan initially, with a total potential of up to $500 million. MannKind said that the agreement was made in… Read more . . .
-
Ethris has announced the initiation of a Phase 2a trial of its intranasal ETH47 mRNA-based antiviral in asthma patients. The Phase 2a study is expected to enroll 50 adult patients who will receive either ETH47 or… Read more . . .
-
Alveolus Bio, which is developing inhaled therapies for the treatment of respiratory diseases, announced that Indian API manufacturer and CDMO Shilpa Medicare Limited has led a strategic financing round that will fund Phase 2 development… Read more . . .
-
AeroRx Therapeutics announced that a Phase 2a trial of its AERO-007 indacaterol / glycopyrrolate inhalation solution demonstrated statistically significant improvements FEV1 versus placebo for both doses studied. According to the company, the inhalation solution is… Read more . . .
-
Rocket Science Health, which recently partnered with Kindeva on development of its nasal delivery device, announced that the US Patent and Trademark Office (USPTO) has issued the company US Patent No. 12,343,489, titled, “Intranasal and… Read more . . .
-
GSK has announced that it will pay $500 million to Hengrui Pharma up front for the rights to Hengrui’s HRS-9821, an inhaled dry powder PDE3/4 inhibitor for the treatment of COPD, plus options to license… Read more . . .
-
According to AstraZeneca, the EMA’s the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion regarding the company’s LGWP version of Trixeo (Breztri) Aerosphere budesonide / glycopyrronium / formoterol MDI, which uses Honeywell’s Solstice… Read more . . .
-
Avalyn Pharma announced that it has closed a $100 million Series D financing, with proceeds intended to support continued development of its inhaled drugs for the treatment of pulmonary fibrosis, including AP01 pirfenidone, AP02 nintedanib,… Read more . . .
-
HCmed Innovations announced that the FDA has granted 510(k) clearance to the company’s AdheResp connected breath-actuated mesh nebulizer, which delivers aerosol during inhalation only. According to the company, AdheResp is the first nebulizer of its… Read more . . .
-
According to ARS Pharmaceuticals, the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the company’s marketing application for EURneffy adrenaline nasal spray for the emergency treatment of anaphylaxis in patients who weigh more than 30… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA